Conference Day 2: 21 March 2012

Conference Day 1: 20 March 2012 ›

Conference Day 2: 21 March 2012 ›

last modified: 16 March '12

Please enable javascript to see more information on speakers

7.30am

CEO Breakfast Forum

Registration and refreshments

9.10am

Chairman’s opening remarks

Promising drug discovery and development strategies in Asia

9.15am

Insights into next generation drug discovery in Singapore

Dr. Alex Matter

"Professor Alex Matter, M.D., is CEO of the Experimental Therapeutics Centre, A*STAR, Singapore, having spent five and a half years as Director of the Novartis Institute for Tropical Diseases (NITD), from October 2003 to February 2009. Prior to this ...

more..

Innovative discovery of drug targets focusing on oncology
Effective utilization of bundles of technology to discover hard targets

› Dr. Alex Matter, CEO of Experimental Therapeutics Centre, A*Star

9.35am

An R&D strategy to achieving “proof of value”

Dr. Shinichi Koizumi

Shinichi Koizumi, Ph.D. has experience in drug discovery more than 20 years and is one of founders of RaQualia and currently serving as Head of Research and CSO. Before starting RaQualia Shinichi was responsible as Head of Biology in Pfizer Central ...

more..

Finding the best approach and key valuation parameter for R&D projects
Differentiating between novel, first in class therapies and other projects at other R&D stages
Application of RaQualia’s “proof of value” business model for effective licensing with partners

› Dr. Shinichi Koizumi, SVP, Research & CSO, RaQualia Pharma

9.55am

Lead discovery strategy at Institut Pasteur Korea

Dr. Michel Liuzzi

Michel Liuzzi, Ph.D., has served as Director, Early Discovery Program at the Institut Pasteur Korea, Seoul (Korea) since January 2011. Prior to that, he was affiliated for 6 years with Idenix Pharmaceuticals Inc., Cambridge (USA) as Senior Director...

more..

Effective use of IPK PhenomicScreen and PhenomicID technologies
Applications in HCV drug discovery and Alzheimer’s disease drug discovery

› Dr. Michel Liuzzi, Director, Early Discovery Program, Institut Pasteur Korea

10.15am

Morning refreshments, exhibition visit and academic poster showcase

Optimising and innovating drug discovery and development

11.05am

Open Innovation in drug discovery

Dr Jiehao Chen

Dr. Jiehao Chen pursued his PhD at the Department of Chemistry of the University of Minnesota and his postdoctoral studies at The Memorial Sloan-Kettering Cancer Center, New York, under the supervision of Professor Samuel Danishefsky. Then Dr. Chen...

more..

› Dr Jiehao Chen, Principle Scientist II, Eli Lilly

11.15am

Natural products for lead discovery: Teaching an old dog new tricks

Dr Martin Everett

Martin Everett joined MerLion in 2005, initially as Head of Biological Sciences, becoming Head of Research in 2008. Before joining MerLion he worked at Glaxo SmithKline in the UK on anti-tubercular drug discovery and led a team performing automated...

more..

Improving efficiency and effectiveness or the discovery process
Applying chemical fingerprinting techniques to the analysis of fermentation extracts
Unlocking the full value of natural product collections

› Dr Martin Everett, Head of Research, MerLion Pharmaceuticals

11.45am

Developing drugs for successful approval in China: A case study

Dr Ying Luo

After receiving his Ph.D. and working in California’s biotech industry for 10 years, Dr. Ying Luo returned to China to found Shanghai Genomics as a new generation Chinese drug discovery company in 2001. He has led three Chinese National “863”...

more..

› Dr Ying Luo, President, Shanghai Genomics

12.05pm

Discovering modern personalized medicine with innovative biomarkers

Dr Iman El-Hariry

Iman is a clinical Oncologist, earned her MD in Alexandria medical school in Egypt, and her PhD at the Imperial college, London, UK. She moved to the Pharmaceutical sector in 1998 and worked as a leader of oncology in GSK for 10 years, based in UK...

more..

Combining innovative biomarkers with mutation assays and digital pathology to develop modern personalized medicine
Pioneering next generation of treatments through biomarkers and related advanced technologies to accelerate future of cancer research
Refining biomarker capabilities through combining therapies: Targeted therapeutic cocktails and typical course of chemotherapeutic- for cost and time effectiveness

› Dr Iman El-Hariry, VP, Clinical Research,, Synta Pharmaceuticals,

12.25pm

Networking luncheon, exhibition visit & academic poster showcase

Ensuring Success in Drug Development through Improved Effectiveness

2pm

Utilizing high throughput technologies in early development to accelerate time to clinic

Sreehari Babu at Drug Discovery World Asia 2012

Understanding the implications of new technologies in early drug development
Overcoming solubility & stability challenges in early drug development with limited amount of material
Employing latest technologies to understand development risks early to improve success rate of new molecules

› Sreehari Babu, Head, Chemical & Pharmaceutical Profiling, Novartis

2.20pm

High throughput quantitative analysis of new chemical entities in biological fluids: can we achieve a 10 second analysis time per sample?

Dr Olivier Heudi

Olivier Heudi obtained his diploma of advanced studies in physiology and pharmacology at Pasteur Institute Paris (France) in 1995 and his Ph.D. in life Sciences at the University of Angers France in 1999. He previously gained experience in the...

more..

High throughput quantitative analysis in biological fluids
Sample preparation protein precipitation and Solid phase extraction
Laser diode thermal desorption and APCI-MS

› Dr Olivier Heudi, Head, Translational Sciences, Novartis Institute for Biomedical Research

2.40pm

Translation imaging for CNS drug discovery and development

Dr Chih-Liang Chin

Chih-Liang Chin, Ph.D. is Director and Site Lead Imaging, Translational Medicine Research Centre at Merck & Sharp Dohme, Singapore. In this role, Chih-Liang provides leadership and coordination for the development of translational imaging biomarker ...

more..

Formulating operational strategies of biomarker research process to reduce costs in R&D
Optimizing biomarkers and pharmacodynamics indicators for drug response and toxicity during drug discovery process
Developing innovative approaches to validate biomarkers to accelerate approval of biomarkers in drug development process

› Dr Chih-Liang Chin, Director and Site Lead, Imaging, MSD/ Translation Medicine Research Centre

3pm

Afternoon refreshments, exhibition visit and academic poster showcase

Promising research and technology developments

4pm

The current status of the first-in-class dual inhibitor of PI3K and Erk AEZS-132

Dr Michael Teifel

Dr. Teifel completed his doctoral thesis on the optimization of non-viral gene transfer to mammalian cells in biology and received his Dr. rer. nat. (Ph.D.) in 1996 from the Technical University of Darmstadt. After completion of his doctoral...

more..

Evaluating the first-in-class Erk and dual PI3K/Erk inhibitor
Proven in-vivo pharmalogical activities in cancer xenograft models
Forward looking application possibilities and development opportunities

› Dr Michael Teifel, Vice President Preclinical Development, Æterna Zentaris GmbH

4.20pm

Deduction of novel phenotypes and disease mechanisms in uropathogenic E.coli using comparative evolutionary analysis

Dr. Swaine Chen

Swaine Chen received his Ph.D. in Developmental Biology and an M.D. from Stanford University in 2004. He became interested in applying computational tools to infectious diseases during his post-doc in the lab of Scott Hultgren, Ph.D. at Washington...

more..

Analysing a case study to making use of increased DNA sequence availability
Effective translation of sequence data in silico into new mechanistic insights in vivo using the FimH protein
Advantages of in silico evolutionary approaches for identification of in vivo phenotypes

› Dr. Swaine Chen, Senior Investigator, NUS, Genome Insititute of Singapore

4.40pm

Accelerating drug discovery with fluorescent-tagged antimalarials

Dr Kevin Tan

Dr. Kevin Tan pursued his PhD at the Department of Microbiology NUS and his postdoctoral studies at the Laboratory of Molecular Parasitology, The Rockefeller University, New York, under the supervision of Professor George Cross. Upon his return to...

more..

New cell death mechanisms in malaria parasites revealed through fluorescent-tagged chloroquine
Differentiation between chloroquine sensitive and resistant strains
Rapid screening for co-drugs restoring chloroquine sensitivity in resistant parasites